CN101675078A - CRIg拮抗剂 - Google Patents

CRIg拮抗剂 Download PDF

Info

Publication number
CN101675078A
CN101675078A CN200880014866A CN200880014866A CN101675078A CN 101675078 A CN101675078 A CN 101675078A CN 200880014866 A CN200880014866 A CN 200880014866A CN 200880014866 A CN200880014866 A CN 200880014866A CN 101675078 A CN101675078 A CN 101675078A
Authority
CN
China
Prior art keywords
crig
antibody
thr
leu
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880014866A
Other languages
English (en)
Chinese (zh)
Inventor
门诺·范卢克伦坎佩恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39645433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101675078(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN101675078A publication Critical patent/CN101675078A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880014866A 2007-05-01 2008-04-25 CRIg拮抗剂 Pending CN101675078A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91534007P 2007-05-01 2007-05-01
US60/915,340 2007-05-01
PCT/US2008/061513 WO2008137338A1 (en) 2007-05-01 2008-04-25 CRIg ANTAGONISTS

Publications (1)

Publication Number Publication Date
CN101675078A true CN101675078A (zh) 2010-03-17

Family

ID=39645433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880014866A Pending CN101675078A (zh) 2007-05-01 2008-04-25 CRIg拮抗剂

Country Status (16)

Country Link
US (1) US20090162356A1 (enExample)
EP (1) EP2152749A1 (enExample)
JP (1) JP2010526076A (enExample)
KR (1) KR20100018523A (enExample)
CN (1) CN101675078A (enExample)
AR (1) AR066375A1 (enExample)
AU (1) AU2008247958A1 (enExample)
BR (1) BRPI0810926A2 (enExample)
CA (1) CA2682835A1 (enExample)
CL (1) CL2008001238A1 (enExample)
IL (1) IL201165A0 (enExample)
MX (1) MX2009011407A (enExample)
PE (1) PE20090239A1 (enExample)
RU (1) RU2009144280A (enExample)
WO (1) WO2008137338A1 (enExample)
ZA (1) ZA200906812B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105924515A (zh) * 2016-04-25 2016-09-07 中国人民解放军第三军医大学 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用
CN113423728A (zh) * 2018-09-28 2021-09-21 优特力克斯有限公司 抗人vsig4抗体及其应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
LT2280996T (lt) * 2008-05-06 2016-12-12 Genentech, Inc. Subrendusio giminingumo crig variantai
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10752689B2 (en) * 2017-06-26 2020-08-25 Bio-Techne Corporation Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using
WO2020236626A1 (en) * 2019-05-17 2020-11-26 Herzlinger George A Methods and systems for treating microbial disease
MX2022002672A (es) * 2019-09-04 2022-06-16 Y Biologics Inc Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
KR20230156727A (ko) 2021-03-03 2023-11-14 피에르 파브르 메디카먼트 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105924515A (zh) * 2016-04-25 2016-09-07 中国人民解放军第三军医大学 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用
CN105924515B (zh) * 2016-04-25 2019-06-14 中国人民解放军第三军医大学 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用
CN113423728A (zh) * 2018-09-28 2021-09-21 优特力克斯有限公司 抗人vsig4抗体及其应用
CN113423728B (zh) * 2018-09-28 2024-03-01 优特力克斯有限公司 抗人vsig4抗体及其应用

Also Published As

Publication number Publication date
AR066375A1 (es) 2009-08-12
IL201165A0 (en) 2010-05-17
KR20100018523A (ko) 2010-02-17
AU2008247958A1 (en) 2008-11-13
PE20090239A1 (es) 2009-03-19
CA2682835A1 (en) 2008-11-13
MX2009011407A (es) 2009-11-05
US20090162356A1 (en) 2009-06-25
EP2152749A1 (en) 2010-02-17
JP2010526076A (ja) 2010-07-29
RU2009144280A (ru) 2011-06-10
BRPI0810926A2 (pt) 2014-11-04
CL2008001238A1 (es) 2008-11-07
WO2008137338A1 (en) 2008-11-13
ZA200906812B (en) 2010-12-29

Similar Documents

Publication Publication Date Title
CN101675078A (zh) CRIg拮抗剂
JP2022084942A (ja) Ｃｔｌａ４に結合する抗体医薬
KR101545795B1 (ko) 치료학적 항체에 대한 조성물 및 사용 방법
US8329178B2 (en) Antibodies against CXCR4 and methods of use thereof
EP2102661B1 (en) Modulators of neuronal regeneration
AU2001281163A1 (en) Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
EP1307225A2 (en) Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l
JP2015108015A (ja) Ｉｌ−１７ａ／ｆヘテロ二量体ポリペプチドおよびその治療上の使用
CN101720232A (zh) 具有修饰的效应器功能的fc受体结合型多肽
JP2015145397A (ja) 抗α２インテグリン抗体を使用する処置
US8197811B2 (en) Methods of use of sialoadhesin factor-2 antibodies
KR20180021136A (ko) 항-혈관 내피 성장 인자 수용체 2 (vegfr2) 항체
AU2008335245A1 (en) Modulators of neuronal regeneration
JP2011523359A (ja) 抗ＰｉｒＢ抗体
JP2007525416A (ja) 早期活性化分子のターゲティングに基づく免疫調節
US20090285803A1 (en) ANTI-PirB ANTIBODIES
JP2020504597A (ja) Ｃｄ６のリン酸化を低減させるためのイトリズマブの使用
US20100047232A1 (en) Modulators of neuronal regeneration
US20220220199A1 (en) Anti-lag-3 binding molecules
JP2003525615A (ja) シアロアドへジンファクター−２抗体
HK1259426B (zh) Pd-l1抗体及其用途
HK1259426A1 (zh) Pd-l1抗体及其用途
HK1243006A1 (zh) 抗trem2抗体及其使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100317